TGTX
Q4 2026 EPS Estimate
$0.36
Nov 2, 2026 · Reports before open
Revenue Estimate
$247M
FY2026E EPS$1.10
FY2027E EPS$2.96

Analyst Sentiment

Wall St. Consensus
Buy
13 analysts·Moderate coverage
69
Score
11 Buy (85%)1 Hold (8%)1 Sell (7%)
Rating Breakdown
Strong Buy
00%
Buy
1185%
Hold
18%
Sell
18%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$78.00
+58.3%
Consensus
$80.50
+63.4%
Bull
$83.00
+68.4%
12-Month Target Range13 analysts
$78.00$80.50$83.00
Current $49.28Consensus
Current Price
$49.28
Upside to Consensus
$31.22

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+37.42%
EPS+167.84%
FY2028
Rev+24.73%
EPS+25.56%
FY2029
Rev+16.28%
EPS+14.28%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$956M$1.31B$1.64B$1.90B$2.23B
Low$954M$1.24B$1.48B$1.80B$2.11B
High$958M$1.40B$1.88B$2.04B$2.39B
EBITDA Avg$-290M$-399M$-498M$-578M$-678M
Low$-291M$-426M$-571M$-619M$-725M
High$-290M$-378M$-448M$-548M$-642M
EBIT Avg$-291M$-400M$-499M$-580M$-679M
Low$-291M$-427M$-572M$-620M$-726M
High$-290M$-379M$-449M$-549M$-643M
Net Income Avg$144M$456M$523M$685M$865M
Low$102M$355M$500M$638M$806M
High$222M$703M$681M$747M$944M
EPS Avg$1.10$2.96$3.71$4.24$5.36
Low$0.63$2.20$3.10$3.95$5.00
High$1.38$4.35$4.22$4.63$5.85
Analysts (Rev / EPS)5 / 56 / 65 / 52 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$246M$268M$281M$311M$336M$369M
Low$244M$262M$275M$305M$329M$362M
High$247M$278M$290M$321M$347M$382M
EBITDA Avg$-75M$-81M$-85M$-94M$-102M$-112M
Low$-75M$-84M$-88M$-98M$-105M$-116M
High$-74M$-80M$-84M$-93M$-100M$-110M
EBIT Avg$-75M$-82M$-86M$-95M$-102M$-112M
Low$-75M$-85M$-88M$-98M$-106M$-116M
High$-74M$-80M$-84M$-93M$-100M$-110M
Net Income Avg$59M$72M$78M$98M$113M$87M
Low$40M$51M$76M$95M$110M$85M
High$74M$91M$81M$102M$118M$91M
EPS Avg$0.37$0.46$0.49$0.62$0.72$0.56
Low$0.25$0.32$0.48$0.60$0.70$0.54
High$0.47$0.58$0.52$0.65$0.75$0.58
Analysts (Rev / EPS)5 / 45 / 44 / 14 / 14 / 14 / 1

Earnings Surprises

Recent Analyst Actions

Aug 4, 2026H.C. Wainwright
TG Therapeutics (TGTX) PT Raised to $78 at H.C. Wainwright
Target:$78.00
+68.9%from $46.17
Jun 22, 2026Jefferies
TG Therapeutics price target raised to $83 from $57 at Jefferies
Target:$83.00
+52.6%from $54.40
May 6, 2026H.C. Wainwright
TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright
Target:$70.00
+76.1%from $39.75
Jan 15, 2026Goldman Sachs
TG Therapeutics price target raised to $39 from $37 at Goldman Sachs
Target:$39.00
+32.0%from $29.54
Oct 6, 2025H.C. Wainwright
TG Therapeutics assumed with a Buy at H.C. Wainwright
Target:$60.00
+63.5%from $36.70
Nov 5, 2024H.C. Wainwright
TG Therapeutics (TGTX) PT Raised to $55 at H.C. Wainwright
Target:$55.00
+325.4%from $12.93
Aug 6, 2024Goldman Sachs
TG Therapeutics price target raised to $20 from $18 at Goldman Sachs
Target:$20.00
-2.8%from $20.58
May 3, 2024H.C. Wainwright
TG Therapeutics (TGTX) PT Raised to $49 at H.C. Wainwright
Target:$49.00
+496.8%from $8.21
Feb 7, 2023Cantor Fitzgerald
Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $24
Target:$24.00
+29.9%from $18.48
Dec 30, 2022Evercore ISI
Evercore ISI Group Maintains Outperform on TG Therapeutics, Raises Price Target to $16
Target:$16.00
+35.2%from $11.83
Dec 29, 2022H.C. Wainwright
TG Therapeutics price target raised to $24 from $19 at H.C. Wainwright
Target:$24.00
+467.4%from $4.23
Apr 19, 2022Goldman Sachs
Goldman Sachs Maintains Sell on TG Therapeutics, Lowers Price Target to $5
Target:$5.00
-31.1%from $7.26
Apr 18, 2022Telsey Advisory
Has TG Therapeutics Stock Hit Bottom? Looking for the Silver Lining
Target:$23.00
+564.7%from $3.46
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.